ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]